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A B S T R A C T
Background
In neovascular age-related macular degeneration (AMD) new vessels grow under the retina distorting vision and leading to scarring.
This is exacerbated if the blood vessels leak. Photodynamic therapy (PDT) has been investigated as a way to treat the neovascular
membranes without affecting the retina.
Objectives
The aim of this review was to examine the effects of PDT in the treatment of neovascular AMD.
Search strategy
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which includes the Cochrane Eyes and Vision Group
Trials Register) on The Cochrane Library (Issue 1, 2005), MEDLINE (1966 to January 2005), EMBASE (1980 to January 2005). We
used the Science Citation Index to search for reports that cited relevant studies. We contacted experts in the field and searched the
reference lists of relevant studies.
Selection criteria
We included randomised trials of PDT in people with choroidal neovascularisation due to AMD.
Data collection and analysis
Two authors independently extracted the data. Relative risks were combined using a fixed-effect model after testing for heterogeneity.
Main results
Two published trials were identified that randomised 948 participants to verteporfin therapy compared to 5% dextrose in water. Both
trials were performed by the same investigators using largely the same clinical centres and funded by manufacturers of verteporfin.
Outcome data were available at 12 and 24 months after the first treatment. Participants received on average five treatments over two
years. The relative risk of losing three or more lines of visual acuity at 24 months comparing the intervention with the control group
was 0.77 (95% confidence interval 0.69 to 0.87). The relative risk of losing six or more lines of visual acuity at 24 months comparing
the intervention with the control group was 0.62 (95% confidence interval 0.50 to 0.76). The results at 12 months were similar to
those at 24 months. The most serious adverse outcome, acute (within 7 days of treatment) severe visual acuity decrease, occurs in about
one in 50 patients.
Authors’ conclusions
Photodynamic therapy in people with choroidal neovascularisation due to AMD is probably effective in preventing visual loss though
there is doubt about the size of the effect. Outcomes and potential adverse effects of this treatment should be monitored closely. Further
independent trials of verteporfin are required to establish that the effects seen in this study are consistent and to examine important
issues not yet addressed, particularly relating to quality of life and cost.
1Photodynamic therapy for neovascular age-related macular degeneration (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
P L A I N L A N G U A G E S U M M A R Y
Photodynamic therapy may reduce vision loss caused by one type of age-related macular degeneration but more research is needed
Age-related macular degeneration (AMD) affects the macula, the centre of the retina (the light-sensitive area inside the eye). One type
is called ’wet’ or neovascular AMD, as new blood vessels develop in the macula. These can leak and scar the eye causing vision loss.
Photodynamic therapy involves injecting chemicals into the blood stream then radiating light as the chemicals flow through these new
blood vessels in the eye. This aims to activate the chemicals enough to destroy the vessels but not enough to hurt the eye. The review
found evidence that this may reduce vision loss caused by neovascular AMD but more research is needed.
B A C K G R O U N D
Age-relatedmacular degeneration (AMD) is a disease affecting the
macula, the central area of the retina. The disease is defined as
degeneration of the macula in older people (aged over 50) with no
other apparent cause for the degeneration.
There are several signs in the retina that are associated with in-
creasing age and increased risk of developing age-related macular
degeneration. These signs, known as age-related maculopathy, in-
clude the presence of drusen (yellow spots beneath the retina) and
pigmentary disturbance. In general age-relatedmaculopathy is not
associated with visual loss. Some people with age-related macu-
lopathy will go on to develop age-related macular degeneration.
There are two main types of AMD. In geographic atrophy (dry)
AMD, the retinal pigment epithelium is lost completely in lo-
calised areas. In neovascular (wet) AMD, sub-retinal neovascular
membranes (new blood vessels) develop beneath the retina. These
are associated with scarring of the retina that affects vision. The
new vessels can leak causing haemorrhage that leads to larger scars
or macular oedema and significant loss of vision. This review was
concerned with treatment for neovascular age-related macular de-
generation.
Sub-retinal neovascular membranes are defined as classic or oc-
cult according to their appearance on fluorescein angiography, in
which fluorescent dye is injected intravenously and photographed
as it passes through the blood vessels of the eye. Classic membranes
are clearly delineated and leak fluorescein uniformly. Occultmem-
branes are often hidden or their extent is hard to delineate, and
fluorescein leakage is patchy. It is thought that these two angio-
graphic patterns reflect the different extent to which the vessels
have penetrated the retinal pigment epithelium, occult vessels ly-
ing underneath the retinal pigment epithelium. Some lesions may
have both classic and occult components.
Trials have shown that early laser photocoagulation of classic ex-
trafoveal membranes (those not directly underneath the fovea at
the centre of the macula) could delay the loss of vision in a small
number of patients (MPS 1994). However, most patients present
with subfoveal membranes, and whilst photocoagulation can limit
the extent of the subsequent visual loss, it causes immediate loss of
central vision due to the concurrent destruction of the overlying
retina.
Photodynamic therapy, originally used in the treatment of cancer,
has been investigated as a way to treat the neovascular membranes
without affecting the retina. Photoreactive chemicals are injected
into the patient and irradiated with light as they pass through the
neovascular membranes. This light is strong enough to activate
the chemicals, causing them to emit free radicals that destroy the
blood vessels, but is not strong enough to cause damage to the
overlying retina.
O B J E C T I V E S
The aim of this review was to examine the effects of photodynamic
therapy in the treatment of neovascular age-related macular de-
generation.
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
We included randomised controlled trials.
Types of participants
We included trials in which participants were people with neo-
vascular age-related macular degeneration as defined by the study
investigators.
Types of intervention
We included any study in which photodynamic therapy was com-
pared to another treatment, placebo or no treatment.
Types of outcome measures
The primary outcome for this review was prevention of visual
loss. Any well-defined outcome based on visual acuity was used
depending on the way in which authors presented trial data. Other
validated measures of visual loss, such as contrast sensitivity, were
used where available.
The secondary outcomes for this review were:
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• new vessel growth;
• quality of lifemeasures - any validatedmeasurement scale which
aims to measure the impact of visual function loss on quality of
life of participants;
• any adverse outcomes as reported in trials.
S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: methods used in reviews.
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) (which contains the Cochrane Eyes and Vision
Group Trials Register) on The Cochrane Library, MEDLINE and
EMBASE.
We used the following strategy to search CENTRAL Issue 1,
2005:
#1 MACULAR DEGENERATION
#2 RETINAL DEGENERATION
#3 NEOVASCULARIZATION PATHOLOGIC
#4 (macula* or retina* or choroid*)
#5 (degenerat* or neovascular*)
#6 (#4 and #5)
#7 maculopath*
#8 (#1 or #2 or #3 or #6 or #7)
#9 PHOTOCHEMOTHERAPY
#10 PHOTOSENSITIZING AGENTS
#11(photosensit* or photodynamic* or pdt or verteporfin or
visudyne)
#12 (#9 or #10 or #11)
#13 (#8 and #12)
We used the following strategy combined with the Cochrane
highly sensitive search strategy (Higgins 2005a) to search
MEDLINE on SilverPlatter to January 2005.
#1 explode “Macular-Degeneration” / all SUBHEADINGS in
MIME,MJME
#2 explode “Retinal-Degeneration” / all SUBHEADINGS in
MIME,MJME
#3 explode “Choroidal-Neovascularization” / all
SUBHEADINGS in MIME,MJME
#4 ( ((macul* or retina* or choroid*)near (degener* or neovasc*))
in TI )or( ((macul* or retina* or choroid*)near (degener* or
neovasc*)) in AB )
#5 maculopath* in TI
#6 maculopath* in AB
#7 #1 or #2 or #3 or #4 or #5 or #6
#8 explode “Photochemotherapy-” / all SUBHEADINGS in
MIME,MJME
#9 explode “Photosensitizing-Agents” / all SUBHEADINGS in
MIME,MJME
#10 ( ((photosenstiti* near agent*)or porphyrin* or
benzoporphyrin*) in AB )or( ((photosenstiti* near agent*)or
porphyrin* or benzoporphyrin*) in NM )or( ((photosenstiti*
near agent*)or porphyrin* or benzoporphyrin*) in TI )
#11 ( (photodynamic* or PDT) in AB )or( (photodynamic* or
PDT) in TI )
#12 ( (verteporfin or visudyne) in AB )or( (verteporfin or
visudyne) in TI )
#13 #8 or #9 or #10 or #11 or #12
#14 #7 and #13
We used the following strategy to search EMBASE on Ovid to
January 2005.
1. exp Retina Macula Age Related Degeneration/
2. exp Retina Degeneration/
3. exp “Neovascularization (Pathology)”/
4. exp Subretinal Neovascularization/
5. ((macul$ or retina$ or choroid$) adj5 (degener$ or
neovasc$)).ab,ti.
6. maculopath$.ab,ti.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp Photodynamic Therapy/
9. exp Photosensitizing Agent/
10. (photodynamic$ or PDT).ab,ti.
11. (photosensit$ adj3 agent$).ab,ti.
12. (verteporfin or visudyne).ab,tn,ti.
13. 8 or 9 or 10 or 11 or 12
14. 7 and 13
To identify randomised controlled trials we combined this search
with the following strategy.
#1 Randomized Controlled Trial/
#2 exp Randomization/
#3 Double Blind Procedure/
#4 Single Blind Procedure/
#5 random$.ab,ti.
#6 #1 or #2 or #3 or #4 or #5
#7 (animal or animal experiment).sh.
#8 human.sh.
#9 #7 and #8
#10 #7 not #9
#11 #6 not #10
#12 Clinical Trial/
#13 (clin$ adj3 trial$).ab,ti.
#14 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or
mask$)).ab,ti.
#15 exp PLACEBO/
#16 placebo$.ab,ti.
#17 random$.ab,ti.
#18 experimental design/
#19 Crossover Procedure/
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#20 exp Control Group/
#21 exp LATIN SQUARE DESIGN/
#22 #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or
#20 or #21
#23 #22 not #10
#24 #23 not #11
#25 exp Comparative Study/
#26 exp Evaluation/
#27 exp Prospective Study/
#28 (control$ or prospectiv$ or volunteer$).ab,ti.
#29 #25 or #26 or #27 or #28
#30 #29 not #10
#31 #30 not (#11 or #23)
#32 #11 or #24 or #31
Manual searches
We used the Science Citation Index to search for reports that
cited relevant study reports. We contacted experts in the field for
information about further trials and we searched the reference
lists of relevant studies for further trial reports.
M E T H O D S O F T H E R E V I E W
Selection of trials
Two authors independently scanned the titles and abstracts
resulting from the electronic searches. We obtained full copies of
all potentially or definitely relevant articles. Two review authors
assessed the full copies according to the ’Criteria for considering
studies for this review’. Only articles meeting these criteria were
assessed for quality.
Assessment of methodological quality
Two authors independently assessed study quality according to
methods set out in Section 6 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2005b). The authors
were not masked to any trial details during the assessment. Four
parameters of quality were considered: allocation concealment
and method of allocation to treatment, masking of providers
and recipients of care, masking of outcome assessment, and
completeness of follow up. Each parameter of trial quality was
graded: A (adequate); B (unclear); C (inadequate). Disagreement
between the review authors on assessments was resolved by
discussion. We contacted the trial authors for clarification on
any parameter graded B and we excluded any trial scoring C on
allocation concealment.
Data collection
Two authors independently extracted data using a form developed
by the Cochrane Eyes and Vision Group (available from the
editorial base). We resolved discrepancies by discussion. Two
review authors independently entered data into RevMan 4.2 and
we checked any inconsistencies between the two against the study
report.
Data synthesis
Our original data analysis plan was to summarise data from studies
collecting similar outcome measures with similar follow-up times
using the Peto method, after testing for heterogeneity between
trial results using a standard chi squared test. The main outcome
analysed, loss of three or more lines of visual acuity at 12 and
24 months follow up, occurred relatively frequently in the trial
cohort. The odds ratio, therefore, does not approximate to the
relative risk. We present relative risks in this review. We planned
to conduct sensitivity analyses to determine the effect of excluding
studies given a grade of C (inadequate) on any parameter of quality
but to date this has not been necessary.
D E S C R I P T I O N O F S T U D I E S
Finding the trials
The original electronic searches identified 76 reports. We found
one randomised controlled trial (TAP 1999). Since the searches
were updated in February 2001, May 2002 and January 2003
one further study was identified and included in the review (VIP
2001).
A further search update was conducted in January 2005. A to-
tal of 284 new reports were found. No reports of new trials were
found though there were a number of new reports from exist-
ing trials including new outcomes on contrast sensitivity (Rubin
2002), central visual field function (Schmidt-Erfurth 2004) and
subretinal neovascular morphology (Schmidt-Erfurth 2003). In
addition we found one systematic review (Meads 2004), a meta-
analysis of safety results in TAP and VIP (Azab 2004) and a cost-
utility analysis (Hopley 2004). A report on severe visual acuity
decrease in TAP and VIP (Arnold 2004) was also considered rel-
evant. An outcome study reporting visual function and related
quality of life was found (Armbrecht 2004). A number of papers
from the TAP and VIP studies were found including guidelines
for evaluation of fluorescein angiographic findings and treatment
(Barbazetto 2003), determinants of outcome according to lesion
size, visual acuity and lesion composition (Blinder 2003), baseline
lesion composition’s impact on vision outcome (Bressler 2002)
and natural history of minimally classic lesions (Bressler 2004).
We found no reports from the studies identified in the ’Charac-
teristics of ongoing trials’ table but one traditional review of PDT
(Woodburn 2002) mentions trials on other agents, such as etiop-
urpurin (Purlytin) and motexafin lutetium (Optrin) undergoing
phase III and phase II trials respectively.
Summary of the characteristics of included studies
Below is a summary of the included studies. Details can be found
in the ’Characteristics of included studies’ table.
TAP 1999 was a multicentre study investigating the safety and
effectiveness of verteporfin (Visudyne; CIBA Vision Corp, USA).
It was conducted in 22 ophthalmology practices in Europe and
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North America. Participants were people with subfoveal choroidal
neovascularisation (CNV) caused by age-related macular degener-
ation. The majority of participants were white (98%) with a mean
age of 75 years. TAP 1999 was originally devised as two concur-
rent trials in order to comply with regulatory agency requirements.
The study protocols were identical. Ten of the clinical centres were
assigned to study A and 12 to study B. As the results of the trials
were similar and the investigators analysed and presented the data
as one trial we have also assessed it as one trial.
TheVIP 2001 studywas very similar to the TAP1999 study. It was
conducted in 28 practices, most of whom had also participated
in TAP 1999. As for TAP 1999, the majority of participants were
white (98%) with a mean age of 75 years.
In both trials verteporfin (6 mg/m2 body surface area) was com-
pared to placebo (5% dextrose in water) administered via intra-
venous infusion of 30 ml over 10 minutes. This was followed after
15 minutes by application of 83 seconds of laser light at 689 nm
delivered 50 joules/cm² at an intensity of 600 mW/cm² using a
spot size with a diameter 1000 microns larger than the greatest
linear dimension of the CNV lesion.
Participants in TAP 1999 were reviewed every three months when
visual acuity wasmeasured and repeat fluorescein angiography per-
formed. If the trial surgeon judged a recurrence of the membrane
to be present or a persistence of the previous lesion, then repeat
treatment was undertaken. In the phase one and two studies it was
concluded that up to five treatments were necessary to stabilise the
situation (Miller 1999; Schmidt-Erfurth 1999). In the first year
a mean of 3.4 treatments were delivered to the treatment group
and 3.7 to the control group. In the second year a mean of 2.2
treatments were delivered to the treatment group and 2.8 to the
controls group.
Visual acuity was measured in VIP 2001 at 12 and 24 months.
The report of the study did not indicate the mean number of
treatments delivered for all participants. However, in the subgroup
with occult CNV (76% of all participants) 3.1 treatments were
given in the treatment group and 3.5 in the control group. In the
second year, 1.8 and 2.4 treatments were given in the verteporfin
and control groups respectively.
M E T H O D O L O G I C A L Q U A L I T Y
Both TAP 1999 and VIP 2001 were high quality studies with a
very similar study design.
Allocation of treatment group was by opaque serially-numbered
sealed envelopes and was stratified by clinical centre. The baseline
characteristics of the participants by treatment group were pub-
lished. The groups were well balanced with respect to a variety of
demographic and clinical variables. Only one eye per person was
treated.
Reasonable attempts weremade tomask the ophthalmologist, par-
ticipant, vision examiner and Photograph Reading Center per-
sonnel to the treatment assigned. As verteporfin and placebo were
different colours (green versus colourless), the solutions and the
intravenous tubing were covered with foil. The fundus appearance
does not change during treatment to indicate whether verteporfin
or placebo had been infused. There is no other physical evidence
of treatment as verteporfin dye is excreted in the faeces and does
not cause any colour change, and does not alter the colour of
the skin or urine. It was therefore unlikely that participants were
aware of their treatment status. In TAP 1999 the study investiga-
tors reported two instances where the participants were unmasked,
and four cases where the ophthalmologists were unmasked, having
noted a green solution.
Rates of follow up were high in both studies. In TAP 1999 94%
were seen at 12 months and 87% at 24 months. Follow up was
similar between the two treatment groups. The analysis was inten-
tion-to-treat and subgroup analyses were planned a priori (Bressler
N, personal communication). In VIP 2001 93% were seen at 12
months and 86% at 24 months. All participants were included in
the analyses and missing values were imputed using the method
of last observation carried forward.
R E S U L T S
The realistic aim of photodynamic therapy is to slow progression
of age-related macular degeneration, not to produce normal vi-
sion. Outcomes are therefore expressed as risks of a poor outcome,
rather than as improvements in vision. All results are based on
the comparison of people randomised to receive verteporfin with
those randomised to receive placebo (control).
Overall analysis
Loss of three or more lines of visual acuity
A total of 948 participants from TAP 1999 and VIP 2001 were
included in the meta-analysis. At 12 months the pooled relative
risk of losing three or more lines of visual acuity was 0.80 (95%
confidence interval (CI) 0.70 to 0.91) (see Graphs, Comparison
01.01). The relative risk reduction was therefore 0.20 (95% CI
0.09 to 0.30). This analysis was done using a fixed-effect model. A
random-effectsmodel gave a non-significant result, largely because
it placed more weight on the VIP study (pooled relative risk 0.82
(95% CI 0.64 to 1.04).
At 24 months the pooled relative risk was 0.77 (95% CI 0.69
to 0.87) (see Graphs, Comparison 01.02) and the relative risk
reduction was therefore 0.23 (95%CI 0.13 to 0.31). The random-
effects model gave a similar result.
Loss of six or more lines of visual acuity
At 12 months the relative risk of losing six or more lines of visual
acuity was 0.62 (95% CI 0.44 to 0.87) (see Graphs, Comparison
01.03) (TAP 1999 only, data not reported for VIP 2001). The
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relative risk reduction was therefore 0.38 (95% CI 0.13 to 0.56).
At 24 months the pooled relative risk was 0.62 (95% CI 0.50 to
0.76) (seeGraphs, Comparison 01.04). The relative risk reduction
was 0.38 (95% CI 0.24 to 0.50).
Mean number of lines lost
In TAP 1999 themean number of lines of vision lost at 12 months
was 2.2 in the intervention group and 3.5 in the control group.
The difference was 1.3 with fewer lines lost in the intervention
group. The P value for the difference in the mean number of lines
lost was reported as P < 0.001 (Wilcoxon rank sum test). At 24
months the mean number of lines of vision lost was 2.7 in the
intervention group and 3.9 in the control group, a difference of 1.2
lines (P < 0.001). The standard deviations for the mean numbers
of lines lost were not reported and therefore we could not calculate
confidence intervals.
Data on mean number of lines lost for the whole VIP 2001 study
group were not reported.
Subgroup analyses
Subgroup data were available only for the outcome ’loss of three
or more lines of visual acuity’ in TAP 1999 but for both outcomes
(loss of three lines and loss of six lines) in VIP 2001.
Evidence of occult choroidal neovascularisation
In TAP 1999 the relative risks of losing three or more lines of
visual acuity at 12 months were 0.90 if occult choroidal neovascu-
larisation (CNV) was present (95% CI 0.73 to 1.11) and 0.34 if
occult CNVwas absent (95%CI 0.22 to 0.51). At 24 months, the
relative risks were 0.88 (95% CI 0.74 to 1.04) and 0.42 (95% CI
0.30 to 0.60) respectively. The test for effectmodification between
these two subgroups was significant. Neither the 95% confidence
intervals nor the 99% confidence intervals for these two subgroups
overlap.
Lesion area composed of classic choroidal neovascularisation
In TAP 1999 the proportion of the lesion comprised of classic
CNV was estimated as 0%; greater than 0% but less than 50%;
greater than 50%. The proportion was unknown in four partici-
pants (three in the treatment group and one in the control group).
The subgroup analyses were therefore based on a total of 399 eyes.
In VIP 2001 the majority of the participants (76%) had “occult
with no classic CNV”. An additional 56 eyes had some classic
CNV (less than 50% but greater than 0% as above). Only 19 eyes
had predominantly classic CNV.
The pooled relative risks for losing three or more lines of visual
acuity at 12 months for the group with 0% CNV was 0.84 (95%
CI 0.68 to 1.04). Results for three or more lines lost at 12 months
were not reported for the other two subgroups in the VIP 2001
study. In TAP 1999 the relative risk for losing three or more lines
of visual acuity at 12 months in people with more than 0% but
less than 50% CNV was 0.99 (95% CI 0.76 to 1.29) and 0.54
for greater than 50% CNV (95% CI 0.40 to 0.71) (see Graphs,
Comparison 01.05 ).
At 24 months the pooled relative risks for losing three or more
lines of visual acuity were 0.77 (95% CI 0.64 to 0.92), 0.93 (95%
CI 0.77 to 1.14) and 0.60 (95% CI 0.48 to 0.75) respectively (see
Graphs, Comparison 01.06).
These results suggest there was a reduction in the risk of loss of
vision when classic CNV was absent or when greater than 50%
of the lesion was comprised of classic CNV. However there was
very little reduction in risk when between 0% and 50% of the
lesion was comprised of classic CNV. However the test for effect
modification between these three subgroups was not statistically
significant (P = 0.066).
Number needed to treat
We calculated the numbers needed to treat (NNTs) to prevent
one person losing three or more lines and, where possible, one
person losing six or more lines of vision. These NNTs are derived
from the study population, that is, people with subfoveal CNV
and a baseline visual acuity of between 20/40 and 20/200 with
approximately five treatments over two years.
The NNT to prevent one person losing three or more lines of
vision at 24 months was 7.1 (95% CI 4.8 to 12.5). The NNT to
prevent one person losing six or more lines of vision at 24 months
was 7.1 (95% CI 5.0 to 12.5).
Other primary outcomes
Contrast sensitivity
This outcome from the TAP trial was reported by Rubin 2002.
This wasmeasured in participants at baseline and at three-monthly
intervals after refraction and measurement of best-corrected visual
acuity. Contrast sensitivity was measured using the Pelli Robson
chart (no. 7002251 Clement Clarke, Columbus Ohio). The mea-
surements were made using a standard protocol and illumination
and outcomes were categorised in terms of more than 6 or more
than 15 letters lost since baseline. A higher proportion of those
treated with placebo lost both more than 6 and 15 letters of con-
trast sensitivity at 12 and 24 months. The relative risk of losing
6 lines of contrast sensitivity by 24 months was 0.47 (95% confi-
dence interval (CI) 0.37 to 0.60) in the PDT group compared to
placebo (see Graphs, Comparison 01.07). For 15 letters the rela-
tive risk was 0.58 (95% CI 0.34 to 0.98) (seeGraphs, Comparison
01.08).
Central visual field function
This was reported by Schmidt-Erfurth (Schmidt-Erfurth 2004)
for 46 participants of the TAP trial based in Germany. Participants
in this centre had various additional investigations reported in-
cluding Scanning Laser Ophthalmoscopic perimetry of the macu-
lar in order tomeasure the size of the central scotoma in treated and
placebo groups. This was reported as mean area inmm2 Themean
area of the absolute scotoma increased in both groups but signifi-
cantly more the placebo arm (2.5 mm2 baseline to 7.3 mm2at 24
months in the treated group compared to 2.7 mm2 at baseline to
31.5 mm2 at 24 months in the placebo group). Similar findings
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were reported for differences in the increase in size of the relative
scotoma between groups. These differences were reported as statis-
tically significant at the level of P < 0.001 though neither standard
errors of these means nor 95% confidence intervals are provided.
Secondary outcomes
Neovascular membrane morphology
Schmidt-Erfurth’s group also reported on the outcome ofConfocal
Indocyanine Green Angiography on her subgroup of the TAP
trial participants in Germany (Schmidt-Erfurth 2003); in this case
outcomes were reported on 60 participants. It is not clear why
there is a discrepancy between the 60 participants in this analysis
and 46 undergoing measurement of central scotoma as described
above. Presumably 14 patients did not have SLO perimetry but
did have ICG angiography.
This paper reports outcomes in terms of the mean size of the
neovascular membrane in mm2. Forty eyes received PDT and 20
received placebo. Baseline mean areas of ICG leakage were 3.9
mm2 for the PDT group and 2.8 mm2 for the placebo eyes. This
reduced to 3.0 mm2 in the treated group at 24 months compared
to a growth to 9.6 mm2 in placebo eyes. This difference is reported
as highly significant by P value (= 0.008) but no standard errors or
confidence limits are provided apart from graphically represented
error bars which are not specified in the legend.
Quality of life
Evidence of efficacy as described above has still not been substan-
tiated by any quality of life outcomes reported from the TAP or
VIP trials.
Adverse effects
More information on this has become available for this update.
In particular the risk of severe and profound visual loss has been
better estimated. This has been provided by two reports from the
TAP and VIP investigators (Arnold 2004; Azab 2004) and a large
phase 4 open-label study reporting on the outcomes of verteporfin
PDT in 4435 patients called the VAM study (Bessler 2004).
Arnold 2004 focuses on the occurrence of acute severe visual acu-
ity decrease (ASVAD). This was defined as at least a 20 letter loss
(equivalent to four lines) within seven days after treatment. Even
though this paper reports this outcome from two RCTs they de-
scribe the study as an observational case series and a fairly detailed
account is given of 15 events in 14 eyes. One of these was later
judged as unlikely to be due to PDT. All but two events occurred
shortly after the first treatment and only in the treated arm. Three
of these events occurred in the TAP trial and ten in the VIP. All 13
events occurred within three days of treatment. The absolute risk
difference for both studies is 0.02 (95% confidence interval 0.01
to 0.03) (see Graphs, Comparison 01.09). The number needed to
harm (NNH) is estimated to be about 50 (range 30 to 100). That
is one eye will experience ASVAD in 50 treatments.
Azab 2004 provides these data in the context of all other adverse
events reported for the two trials. This report is described as a
meta-analysis though data are only combined for the two trials for
systemic side effects. The authors found that only visual distur-
bances including ASVAD, injection site reactions, photosensitiv-
ity reactions and infusion-related back pain occurred with greater
frequency in the treated participants.
The VAM study (Bessler 2004) reports on outcomes from a larger
number of patients recruited from 222 centres in North America
(10 times the number in TAP) between September 1999 and June
2000 when the verteporfin became commercially available. Max-
imum follow up was therefore nine months. About half the study
population had six months follow up. This study provides further
information on the risk of adverse events outside an RCT setting
but as this is an open label study with no comparator group; rel-
ative risks or risk differences (and hence NNH) cannot be calcu-
lated. However, it is assumed that, as in TAP and VIP, no events
would have occurred in an untreated arm, the risk becomes the
same as the risk difference. Of the 4435 enrolled 115 (2.6%) re-
ported abnormal or decreased vision of whom 25 experienced AS-
VAD (0.6%) (NNH@166). ASVAD is thought to be caused by
bleeding under the retina after PDT. One series from the Wilmer
(Do 2004) reports this outcome in 52 patients but unfortunately
the denominator was not given (the overall number of persons and
eyes receiving PDT). Vision loss can be profound is this group and
data from TAP and VIP suggest it may be more likely to occur in
people with better initial visual acuity.
Reports of visual disturbance (reports of “abnormal vision”, “de-
creased vision” and visual field defect) occurred in one in every
four people taking part in the TAP 1999 and VIP 2001 stud-
ies. This is perhaps unsurprising as participants had neovascular
AMD. However, people treated with verteporfin were more likely
to report visual disturbance (pooled relative risk 1.61, 95% CI
1.24 to 2.09) (see Graphs, Comparison 01.10). Presumably this
visual disturbance must have been reasonably transient as visual
outcomes at 12 and 24 months were better in the treatment group.
2.4% of people treated with verteporfin experienced infusion-re-
lated back pain and 2.4% had photosensitivity reactions. Prob-
lems with the injection site occurred in 13.1% of people treated
with verteporfin compared to 5.6% people in the control group.
Few allergic reactions were seen and these were equally likely in
treatment and control groups.
Economic outcomes
No economic analyses have been reported from either TAP or VIP.
D I S C U S S I O N
The absence to date of any effective treatment for neovascular age-
related macular degeneration (except for the few in whom laser
photocoagulation works) means that there will be intense inter-
est in photodynamic therapy for the many millions of sufferers
of the disease worldwide. Unfortunately photodynamic therapy,
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like photocoagulation, can be effective only during the prolifera-
tive stage of the disease while the neovascular process is active. It
cannot have any effect once sight is lost and the scarring process is
complete. Therefore, like so many other degenerative processes of
the neuroretina, nothing can be done to restore function once the
damage is done. Most sufferers of the condition have established
sight loss and, for these, the publicity surrounding the launch of
Visudyne (verteporfin) will have raised false hopes. However, this
review indicates that for people with active neovascular disease
photodynamic therapy can prevent vision loss. This is corrobo-
rated by additional outcome measures such as contrast sensitivity,
size of central scotoma and neovascular membrane dimensions.
A key question is how long the effect of treatment will last and
whether repeated treatments would be required in the longer term.
This review indicates that treatment benefits last for at least two
years. An open-label extension of the TAP 1999 study indicated
that vision outcomes remained relatively stable from 24 to 48
months (TAP 2002). There have been no further reports of longer
term outcomes.
Another important issue is howmany presenting patients will ben-
efit from photodynamic therapy. In addition to the problem of
accessing specialist services in time, there is the question of the
proportion of lesions that will actually be treatable. The evidence
reported here clearly suggests that purely classic neovascular mem-
branes dowell. Subgroup analysis of the TAP1999 study suggested
that photodynamic therapy is not effective when occult CNV is
present. Occult vessels mean that the extent of the membrane can-
not be clearly defined and so it is not surprising that treatment
is found to be less effective because the laser cannot be aimed
at the entire membrane. However, the VIP 2001 study recruited
mostly patients with occult neovascularisation and demonstrated a
treatment benefit of photodynamic therapy at 12 and 24 months.
Pooled analysis of the TAP 1999 and VIP 2001 studies in this
review showed no statistically significant difference in treatment
effects in subgroups defined by the presence or absence of clas-
sic CNV. This observation has been noted by other authors. For
example, Meads 2004 casts serious doubt on the validity of the
subgroup analyses.
Subsequent reports of “exploratory” analyses (presumably not
specified a priori) have beenpublished from theTAP trials (Bressler
2002) and from the TAP and VIP trials (Blinder 2003) which find
only lesion size (the smaller lesions do better) and poorer present-
ing acuity (perhaps less vision to lose) were predictors of better
outcome. One other report from TAP (Bressler 2004) examined
the natural history of minimally classic lesions which had a poorer
outcome in the TAP trial treated group. Of the 207 randomised
to the placebo group 98 had minimally classic lesions of which 39
progressed to become predominantly classic (21 of these within
three months). The suggestion here is that it might be advisable
to wait for minimally classic lesions to progress to become pre-
dominantly classic so that potential effectiveness of PDT might
be greater. The authors imply that this need not necessarily be at
the expense of allowing the lesion to become very large or indeed
the vision to deteriorate.
We are not told in the available reports the extent to which clini-
cians and indeed the trial Photograph Reading Center personnel
were able to agree about the subgroup classification of classic or
occult lesions. It is likely that there is much variation in opinion
on this. The necessary skill to report on fluorescein angiograms
and recognise different lesion types is highly refined. Most experts
assert that stereo images are required to be able to locate the posi-
tion in depth of staining or fluorescein leaks. Stereophotography
requires either a dedicated camera equipped to take simultaneous
stereo images or a skilled photographer who takes sequential im-
ages slightly laterally displaced from one another, providing a non-
simultaneous or pseudo-stereo image. However, the guidelines for
reporting angiograms and data on interobserver agreement have
now been published for the TAP and VIP trials (Barbazetto 2003).
A lot of detail is given on reporting guidelines but the information
on agreement is somewhat brief though reported kappa values for
the main subgroup criteria were good. This was based on a 10%
subsample of graded photographs. Another independent study has
reported on agreement within and between 16 different specialists
in Germany (Holz 2003) for the same angiographic criteria as for
TAP and VIP. Agreement was not quite so good for both intra and
interobserver agreement as for the reporting centre for the trials
but was acceptable nevertheless.
The natural history of the growth of subretinal membranes varies
from individual to individual. They may be aggressive and rapidly
growing or indolent. This is the kind of individual factor that
will influence the likelihood of a patient being in a position to
benefit from this treatment. The trial report does not comment
on the proportion of participants presenting to the trial centres
that had treatable lesions. The verbal estimate from one trialist
was approximately 25% and from another expert between 5% and
7%. This is of crucial importance in estimating the impact of this
new treatment on healthcare budgets.
Age-related macular degeneration is a bilateral disease although
one eye is usually affected before the other.With a lesion present in
one eye, the annual cumulative incidence of a lesion in the second
eye is estimated to be about 15%.Clinicians now commonly advise
patients with a lesion in one eye to be watchful for the onset
of symptoms in the second eye and to present as soon as those
symptoms are noticed to improve the chances of catching the
lesion in the second eye in time. This often entails the provision of
an Amsler grid, a simple chart on which a number of gridlines are
printed around a central fixation spot. The patient is instructed to
examine the grid and to look for focal distortion of the lines in the
grid which would indicate local elevation of the retina as a result
of the growth of an underlying membrane. This strategy offers the
best hope of saving sight with this new treatment at least in places
where access to a qualified ophthalmologist can be slow.
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It should also be recalled that this treatment does not restore sight
but rather prevents further deterioration. Sustaining numerous as-
sessments which involve relatively invasive treatments may have
an adverse effect on the patient. Without patient-orientated out-
comes in these trials we cannot comment on the patient’s perspec-
tive on the experience of Visudyne therapy. It is likely that in most
cases, especially where loss of sight of the second eye is threatened,
patients will be willing to undergo all the necessary interventions,
even when the probability of success is small.
Quality of life outcomes have been independently reported in a
cohort of individuals treated with PDT and followed for one year
(Armbrecht 2004). There was no comparator group. At 12months
participants were less anxious andmore independent than baseline
though there was a significant deterioration in more vision-related
tasks.
Adverse effects occurred infrequently with the exception of the
rather vague “visual disturbance” which affected more people in
the verteporfin group compared to the control group. However,
this was not reflected in the visual acuity outcomes. Infusion-
related back pain occurred in 2.4% which is substantially lower
than in some other studies. For example, in a series of 250 people
treated with verteporfin 9.6% experienced verteporfin-associated
pain, most of which was back pain (Borodoker 2002). It is now
clear that acute severe visual acuity decrease is a relatively small but
serious risk of poor outcome of treatment. This review estimates
this risk to be approximately one in 50 patients.
The trials included in this review appear to have been performed
to high standards and were closely supervised by the Food and
Drugs Administration of the USA. Both trials were sponsored by
the manufacturers of the drug (CIBA Vision and Novartis Oph-
thalmics) and declared potential conflicts of interest exist for a
number of the trialists who hold interests in the manufacturer of
the laser technology. This makes detailed scrutiny of reports of the
trial essential. Of concern are the numerous protocol revisions that
were registered with the Institutional Review Bodies throughout
the study and after completion of follow up. Although we have
not yet had access to the main protocol or to the revisions, a CIBA
representative has assured us that the changes were not substan-
tive and, in particular, that there were no changes to the a priori
determinants of the primary outcomes.
New reviews have not drawn any conflicting conclusions or any
additional evidence. In particular, the review commissioned by
the National Health Service’s Research and Development Health
Technology Assessment Programme on behalf of the National In-
stitute of Clinical Excellence (NICE) in the UK (accessible at
http://www.nice.org.uk) was in accordance with the findings of
our review but went on to perform a detailed cost and cost-utility
analysis. They concluded through economic modelling that the
benefits of PDT with verteporfin at two years were “at best at the
margins of what is generally considered to be an efficient use of
health care resources”.
Another paper fromAustralia (Hopley 2004) examined cost-utility
for PDT for predominantly classic neovascular AMD using data
from theTAP trial in two cost-utilitymodels for two case scenarios.
They conclude that as the only available treatment for some forms
of neovascular AMD, PDT can be considered moderately cost
effective for those with reasonable acuity but less so for those
with poorer presenting vision. These conclusions depend upon the
validity of the subgroup analyses of the TAP trial and there must
be some concern that one of the conclusions of the trialists post
hoc analyses that those with poorer presenting vision fare better
in terms of numbers of lines of visual acuity lost.
The NICE review concluded that there was still much uncertainty
about the effectiveness of this treatment. In the face of enormous
pressure to provide something that might work when nothing else
is available, provision of service conditional on close monitoring
of outcomes is a pragmatic approach, though implementation of
this policy is difficult.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review provides evidence that photodynamic therapy in peo-
ple with classic and occult choroidal neovascularisation due to age-
related macular degeneration is probably effective in preventing
visual loss though the size of the effect remains in doubt. On the
basis of existing evidence, approximately seven people need to be
treated with an average of five treatments over two years to prevent
one person losing three or more lines of visual acuity. One in every
50 treated patients will have an acute severe loss of vision in the
treated eye. For an expensive treatment there are questions about
the cost-utility and indeed opportunity cost for health services,
especially when resources are limited.
Two trials were included in this review. Both trials were performed
by the same investigators using largely the same clinical centres and
funded bymanufacturers of verteporfin. As for all new technology,
outcomes and potential adverse effects need to bemonitored when
introduced into clinical practice and this recommendation has
been implemented in the UK by the establishment of a national
cohort study to monitor outcomes of verteporfin PDT according
to NICE guidelines in the NHS.
There are major implications for health services, both in terms
of potential expenditure and organisation, if photodynamic ther-
apy is to be introduced. Where referral to an ophthalmologist is
through a primary care network, facilities for the recognition of
this condition in its early stages are needed. There is potential for
an enormous increase in referral of people with early age-related
maculopathy for assessment, in case an early treatable lesion is
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present. This could swamp already overstretched facilities at the
secondary care level. Extra resources will be required at the sec-
ondary care level to manage increased referrals, for the necessary
technology to diagnose treatable lesions and to deliver treatment.
Implications for research
Further independent trials of verteporfin are required to establish
that the effects seen in this study are consistent and to examine
important issues not yet addressed, particularly relating to quality
of life and cost.
A similar recommendationwasmade by the authors commissioned
for NICE for publicly-funded pragmatic trials with economic and
vision-related quality of life outcomes over a longer time scale. To
our knowledge no such studies are underway. Some commentators
argue that technology is progressing at a pace that will render such
studies irrelevant. New interventions for AMD, particularly those
based on drugs active against Vascular Endothelial Growth Factor,
show some promise and there is speculation that the role of PDT-
based treatments will be short-lived.
Descriptive epidemiology on the population at risk and the num-
bers likely to benefit from these kinds of interventions remains
essential to estimate the impact of these new treatments on health
service resources and the well being of the ageing population of
more affluent countries with a life-expectancy sufficient to render
AMD a significant public health concern. A particular concern re-
mains that people in need of treatment can access it equitably and
in time. Health services research of this nature and surveillance for
rare but severe adverse effects is required.
P O T E N T I A L C O N F L I C T O F
I N T E R E S T
None known.
A C K N OW L E D G E M E N T S
TheCochrane Eyes and Vision Group developed and executed the
electronic searches. We would like to thank Neil Bressler, Simon
Harding and Javed Bhatti (CIBA Vision) for providing informa-
tion about the TAP study.UshaChakravarthy (QueensUniversity,
Belfast) and Bob Thompson (Macular Disease Society) provided
useful comments on the review.
S O U R C E S O F S U P P O R T
External sources of support
• No sources of support supplied
Internal sources of support
• Moorfields Eye Hospital NHS Trust UK
R E F E R E N C E S
References to studies included in this review
TAP 1999 {published and unpublished data}
Rubin GS, Bressler NM, the Treatment of Age-Related Macular De-
generation with Photodynamic Therapy (TAP) Study Group. Effects
of verteporfin therapy on contrast sensitivity: results from the treat-
ment of age-related macular degeneration with photodynamic ther-
apy (TAP) investigation - TAP report no. 4. Retina 2002;22(5):536–
44.
∗ Treatment of Age-related Macular Degeneration With Photody-
namic Therapy (TAP) Study Group. Photodynamic therapy of sub-
foveal choroidal neovascularization in age-related macular degenera-
tion with verteporfin: One-year results of 2 randomized clinical tri-
als - TAP report. Archives of Ophthalmology 1999;117(10):1329–45.
[MedLine: 10532441].
Treatment of Age-related Macular Degeneration With Photody-
namic Therapy (TAP) Study Group. Photodynamic therapy of sub-
foveal choroidal neovascularization in age-related macular degenera-
tion with verteporfin: Two-year results of 2 randomized clinical trials
- TAP report 2. Archives of Ophthalmology 2001;119(2):198–207.
[MedLine: 11176980].
Treatment of Age-Related Macular Degeneration with Photody-
namic Therapy (TAP) Study Group. Verteporfin therapy for sub-
foveal choroidal neovascularization in age-related macular degener-
ation: three-year results of an open-label extension of 2 randomized
clinical trials - TAP report no 5. Archives of Ophthalmology 2002;120
(10):1307–14. [MedLine: 12365909].
VIP 2001 {published data only}
Bressler NM. Verteporfin therapy of subfoveal choroidal neovascu-
larization in age-related macular degeneration: two-year results of a
randomized clinical trial including lesions with occult with no classic
choroidal neovascularization - Verteporfin In Photodynamic Ther-
apy Report 2. American Journal of Ophthalmology 2002;133(1):168–
9. [MedLine: 11755871].
∗ Verteporfin in Photodynamic Therapy Study Group. Verteporfin
therapy of subfoveal choroidal neovascularization in age-related
macular degeneration: two-year results of a randomized clinical
trial including lesions with occult with no classic choroidal neo-
vascularization - Verteporfin in Photodynamic Therapy Report 2.
American Journal of Ophthalmology 2001;131(5):541–60. [MedLine:
11336929].
References to studies excluded from this review
Schmidt-Erfurth 1999
Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto
I, Gragoudas ES, et al. Photodynamic therapy with verteporfin for
10Photodynamic therapy for neovascular age-related macular degeneration (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
choroidal neovascularisation caused by age-related macular degener-
ation. Results of retreatment in a phase 1 and 2 study. Archives of
Ophthalmology 1999;117(9):1177–87. [MedLine: 10496389].
References to ongoing studies
ADD-V
Addition of an anti-inflammatory called Voltaren Ophthalmic®.
Ongoing study Starting date of trial not provided. Contact author
for more information.
Japan
Visudyne for CNV due to AMD. Ongoing study Results expected
at end 2003.
VALIO
Altered light treatment using delayed light after Visudyne in occult
AMD. Ongoing study Starting date of trial not provided. Contact
author for more information.
VER
Visudyne in Early Retreatment Phase IIIB clinical trial. Ongoing
study Results expected at end 2003.
VIM
Visudyne in Minimally Classic study. Ongoing study Starting date
of trial not provided. Contact author for more information.
VIO
Visudyne therapy in Occult Phase III trial. Ongoing study Starting
date of trial not provided. Contact author for more information.
Additional references
Armbrecht 2004
Armbrecht AM,Aspinall PA,Dhillon B. A prospective study of visual
function and quality of life following PDT in patients with wet age
related macular degeneration. British Journal of Ophthalmology 2004;
88(10):1270–3.
Arnold 2004
Arnold JJ, BlinderKJ, BresslerNM,Bressler SB, BurdanA,Haynes L,
et al. Acute severe visual acuity decrease after photodynamic therapy
with verteporfin: case reports from randomized clinical trials-TAP
and VIP report no. 3. American Journal of Ophthalmology 2004;137
(4):683–96.
Azab 2004
Azab M, Benchaboune M, Blinder KJ, Bressler NM, Bressler SB,
Gragoudas ES, et al. Verteporfin therapy of subfoveal choroidal neo-
vascularization in age-related macular degeneration: meta-analysis of
2-year safety results in three randomized clinical trials: Treatment
Of Age-Related Macular Degeneration With Photodynamic Ther-
apy and Verteporfin In Photodynamic Therapy Study Report no. 4.
Retina 2004;24(1):1–12.
Barbazetto 2003
Barbazetto I, Burdan A, Bressler NM, Bressler SB, Haynes L,
Kapetanios AD, et al. Photodynamic therapy of subfoveal choroidal
neovascularization with verteporfin: fluorescein angiographic guide-
lines for evaluation and treatment-TAP and VIP report No. 2.
Archives of Ophthalmology 2003;121(9):1253–68.
Bessler 2004
Bessler NM, VAMStudyWriting Committee. Verteporfin therapy in
age-related macular degeneration (VAM): an open-label multicenter
photodynamic therapy study of 4,435 patients. Retina 2004;24(4):
512–20.
Blinder 2003
Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, et
al. Effect of lesion size, visual acuity, and lesion composition on visual
acuity change with and without verteporfin therapy for choroidal
neovascularization secondary to age-related macular degeneration:
TAP and VIP report no. 1. American Journal of Ophthalmology 2003;
136(3):407–18.
Borodoker 2002
Borodoker N, Spaide RF, Maranan L, Murray J, Freund KB, Slakter
JS, et al. Verteporfin infusion-associated pain. American Journal of
Ophthalmology 2002;133(2):211–4.
Bressler 2002
Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish
GE, Gragoudas ES, et al. Verteporfin therapy of subfoveal choroidal
neovascularization in patients with age-related macular degeneration:
additional information regarding baseline lesion composition’s im-
pact on vision outcomes-TAP report No. 3. Archives of Ophthalmol-
ogy 2002;120(11):1443–54.
Bressler 2004
Bressler SB, Pieramici DJ, Koester JM, Bressler M. Natural history
of minimally classic subfoveal choroidal neovascular lesions in the
treatment of age-related macular degeneration with photodynamic
therapy (TAP) investigation: outcomes potentially relevant to man-
agement--TAP report No. 6. Archives of Ophthalmology 2004;122(3):
325–9.
Do 2004
Do DV, Bressler NM, Bressler SB. Large submacular hemorrhages
after verteporfin therapy. American Journal of Ophthalmology 2004;
137(3):558–60.
Higgins 2005a
Higgins JPT, Green S, editors. Locating and selecting studies for re-
views. Cochrane Handbook for Systematic Reviews of Interventions
4.2.4 [updated March 2005]; Section 5. The Cochrane Library, Issue
2, 2005. Chichester, UK: John Wiley & Sons, Ltd.
Higgins 2005b
Higgins JPT, Green S, editors. Assessment of quality. Cochrane
Handbook for Systematic Reviews of Interventions 4.2.4 [updated
March 2005]; Section 6. The Cochrane Library, Issue 2, 2005. Chich-
ester, UK: John Wiley & Sons, Ltd.
Holz 2003
Holz FG, Jorzik J, Schutt F, Flach U, Unnebrink K. Agreement
among ophthalmologists in evaluating fluorescein angiograms in pa-
tients with neovascular age-related macular degeneration for photo-
dynamic therapy eligibility (FLAP-study). Ophthalmology 2003;110
(2):400–5.
Hopley 2004
Hopley C, Salkeld G, Mitchell P. Cost utility of photodynamic ther-
apy for predominantly classic neovascular age related macular degen-
eration. British Journal of Ophthalmology 2004;88(8):982–7.
Meads 2004
Meads C, Hyde C. Photodynamic therapy with verteporfin is effec-
tive, but how big is its effect? Results of a systematic review. British
Journal of Ophthalmology 2004;88(2):212–7.
11Photodynamic therapy for neovascular age-related macular degeneration (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Miller 1999
Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua
H, Barbazetto I, et al. Photodynamic therapy with verteporfin for
choroidal neovascularisation caused by age-related macular degener-
ation. Results of a single treatment in a phase 1 and 2 study. Archives
of Ophthalmology 1999;117(9):1161–73.
MPS 1994
Macular photocoagulation study group. Laser photocoagulation for
juxtafoveal choroidal neovascularization: five year results from ran-
domized clinical trials. Archives of Ophthalmology 1994;112(4):500–
9.
Rubin 2002
Rubin GS, Bressler NM, Treatment of Age Related Macular Degen-
eration with Photodynamic therapy TAP Study Group. Effects of
verteporfin therapy on contrast on sensitivity: Results From theTreat-
ment of Age-Related Macular Degeneration With Photodynamic
Therapy (TAP) investigation-TAP report No 4. Retina 2002;22(5):
536–44.
Schmidt-Erfurth 2003
Schmidt-Erfurth UM, Michels S. Changes in confocal indocyanine
green angiography through two years after photodynamic therapy
with verteporfin. Ophthalmology 2003;110(7):1306–14.
Schmidt-Erfurth 2004
Schmidt-Erfurth UM, Elsner H, Terai N, Benecke A, Dahmen G,
Michels SM. Effects of verteporfin therapy on central visual field
function. Ophthalmology 2004;111(5):931–9.
TAP 2002
Treatment of Age-Related Macular Degeneration with Photody-
namic Therapy (TAP) Study Group. Verteporfin therapy for sub-
foveal choroidal neovascularization in age-related macular degener-
ation: three-year results of an open-label extension of 2 randomized
clinical trials - TAP report no 5. Archives of Ophthalmology 2002;120
(10):1307–14.
Woodburn 2002
Woodburn KW, Engelman CJ, Blumenkranz MS. Photodynamic
therapy for choroidal neovascularization: a review. Retina 2002;22
(4):391–405.
∗Indicates the major publication for the study
T A B L E S
Characteristics of included studies
Study TAP 1999
Methods Randomised controlled trial: one eye per patient was randomised in a 2:1 (treatment:control) ratio
Participants 609 people with subfoveal CNV lesions caused by AMD with evidence of classic CNV and best corrected
acuity of approximately 20/40 to 20/200
Interventions Photodynamic therapy following verteporfin injection versus photodynamic therapy following intravenous
5% dextrose
Outcomes Visual acuity at 12 and 24 months
Notes
Allocation concealment A – Adequate
Study VIP 2001
Methods Randomised controlled trial: one eye per patient was enrolled. Randomisation in sealed envelopes stratified
by clinical centre.
Participants 339 people with subfoveal CNV caused by AMD
Interventions Photodynamic therapy following verteporfin injection versus photodynamic therapy following intravenous
5% dextrose
Outcomes Visual acuity at 12 and 24 months
Secondary outcomes include contrast sensitivity and changes in angiographic outcomes
Notes Randomised 2:1 to verteporfin treatment
Allocation concealment A – Adequate
AMD - age-related macular degeneration
CNV - choroidal neovascularisation
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Characteristics of excluded studies
Study Reason for exclusion
Schmidt-Erfurth 1999 Non-randomised open-label phase I and II trial
Characteristics of ongoing studies
Study ADD-V
Trial name or title Addition of an anti-inflammatory called Voltaren Ophthalmic®
Participants
Interventions
Outcomes
Starting date
Contact information
Notes
Study Japan
Trial name or title Visudyne for CNV due to AMD
Participants
Interventions
Outcomes
Starting date Results expected at end 2003
Contact information Nic Gwatkin, Head of Marketing, Novartis Ophthalmics
Notes
Study VALIO
Trial name or title Altered light treatment using delayed light after Visudyne in occult AMD
Participants
Interventions
Outcomes
Starting date
Contact information Nic Gwatkin, Head of Marketing, Novartis Ophthalmics
Notes
Study VER
Trial name or title Visudyne in Early Retreatment Phase IIIB clinical trial
Participants People with predominantly classic CNV
321 people at 31 sites enrolled
Interventions Visudyne therapy every 3 months (standard) versus more frequent regiment
Outcomes
Starting date Results expected at end 2003
Contact information Nic Gwatkin, Head of Marketing, Novartis Ophthalmics
Notes
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Characteristics of ongoing studies (Continued )
Study VIM
Trial name or title Visudyne in Minimally Classic study
Participants
Interventions Visudyne therapy versus visudyne therapy with reduced light intensity versus placebo
Outcomes
Starting date
Contact information Nic Gwatkin, Head of Marketing, Novartis Ophthalmics
Notes
Study VIO
Trial name or title Visudyne therapy in Occult Phase III trial
Participants People with occult but no classic CNV due to AMD
Interventions
Outcomes
Starting date
Contact information Nic Gwatkin, Head of Marketing, Novartis Ophthalmics
Notes
A N A L Y S E S
Comparison 01. PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Overall effect: >=3 lines lost at
12 months
2 948 Relative Risk (Fixed) 95% CI 0.80 [0.70, 0.91]
02 Overall effect: >=3 lines lost at
24 months
2 948 Relative Risk (Fixed) 95% CI 0.77 [0.69, 0.87]
03 Overall effect: >=6 lines lost at
12 months
Relative Risk (Fixed) 95% CI Totals not selected
04 Overall effect: >=6 lines lost at
24 months
2 948 Relative Risk (Fixed) 95% CI 0.62 [0.50, 0.76]
05 Classic CNV subgroups: >=3
lines lost at 12 months
Relative Risk (Fixed) 95% CI Totals not selected
06 Classic CNV subgroups: >=3
lines lost at 24 months
6 942 Relative Risk (Fixed) 95% CI 0.77 [0.69, 0.87]
07 Overall effect: contrast
sensitivity: >= 6 letters lost at
24 months
Relative Risk (Fixed) 95% CI Totals not selected
08 Overall effect: contrast
sensitivity: >= 15 letters lost at
24 months
Relative Risk (Fixed) 95% CI Totals not selected
09 Adverse effects: acute severe
visual acuity decrease
2 948 Risk Difference (Fixed) 95% CI 0.02 [0.01, 0.03]
10 Adverse effects: visual
disturbance
2 948 Relative Risk (Fixed) 95% CI 1.61 [1.24, 2.09]
11 Adverse effects: injection site 2 948 Odds Ratio (Fixed) 95% CI 2.54 [1.50, 4.31]
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12 Adverse effects: infusion-related
back pain
2 948 Odds Ratio (Fixed) 95% CI 8.40 [1.11, 63.58]
13 Adverse effects: allergic
reactions
2 948 Odds Ratio (Fixed) 95% CI 0.94 [0.34, 2.56]
14 Adverse effects: photosensitivity
reactions
2 948 Odds Ratio (Fixed) 95% CI 5.37 [1.01, 28.60]
I N D E X T E R M S
Medical Subject Headings (MeSH)
Glucose [therapeutic use]; Macular Degeneration [∗drug therapy]; ∗Photochemotherapy; Photosensitizing Agents [∗therapeutic use];
Porphyrins [therapeutic use]; Randomized Controlled Trials; Retinal Neovascularization [∗drug therapy]
MeSH check words
Humans
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Contribution of author(s) RW participated in protocol development, study selection and assessment and writing up
of the original and update of the review.
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and entry and writing up of the original and update of the review.
LS participated in protocol development, study selection and assessment, data abstraction
and entry and writing up of the original and update of the review.
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Issue protocol first published /
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Date of most recent
SUBSTANTIVE amendment
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What’s New No new trials have been identified but new outcomes from existing trials have been reported
on both effectiveness and adverse outcomes.
Date new studies sought but
none found
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G R A P H S A N D O T H E R T A B L E S
Analysis 01.01. Comparison 01 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 01 Overall effect: >=3 lines lost at 12 months
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 01 Overall effect: >=3 lines lost at 12 months
Study PDT Placebo Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
TAP 1999 156/402 111/207 64.0 0.72 [ 0.61, 0.86 ]
VIP 2001 114/225 62/114 36.0 0.93 [ 0.75, 1.15 ]
Total (95% CI) 627 321 100.0 0.80 [ 0.70, 0.91 ]
Total events: 270 (PDT), 173 (Placebo)
Test for heterogeneity chi-square=3.23 df=1 p=0.07 I² =69.0%
Test for overall effect z=3.26 p=0.001
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
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Analysis 01.02. Comparison 01 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 02 Overall effect: >=3 lines lost at 24 months
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 02 Overall effect: >=3 lines lost at 24 months
Study PDT Placebo Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
TAP 1999 189/402 129/207 62.8 0.75 [ 0.65, 0.88 ]
VIP 2001 121/225 76/114 37.2 0.81 [ 0.68, 0.96 ]
Total (95% CI) 627 321 100.0 0.77 [ 0.69, 0.87 ]
Total events: 310 (PDT), 205 (Placebo)
Test for heterogeneity chi-square=0.32 df=1 p=0.57 I² =0.0%
Test for overall effect z=4.41 p=0.00001
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
Analysis 01.03. Comparison 01 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 03 Overall effect: >=6 lines lost at 12 months
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 03 Overall effect: >=6 lines lost at 12 months
Study PDT Placebo Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
TAP 1999 59/402 49/207 0.62 [ 0.44, 0.87 ]
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
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Analysis 01.04. Comparison 01 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 04 Overall effect: >=6 lines lost at 24 months
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 04 Overall effect: >=6 lines lost at 24 months
Study Treatment Placebo Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
TAP 1999 73/402 62/207 53.3 0.61 [ 0.45, 0.81 ]
VIP 2001 67/225 54/114 46.7 0.63 [ 0.48, 0.83 ]
Total (95% CI) 627 321 100.0 0.62 [ 0.50, 0.76 ]
Total events: 140 (Treatment), 116 (Placebo)
Test for heterogeneity chi-square=0.03 df=1 p=0.86 I² =0.0%
Test for overall effect z=4.65 p<0.00001
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours placebo
Analysis 01.05. Comparison 01 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 05 Classic CNV subgroups: >=3 lines lost at 12 months
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 05 Classic CNV subgroups: >=3 lines lost at 12 months
Study PDT Placebo Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
01 No classic CNV
TAP 1999 14/38 13/19 0.54 [ 0.32, 0.90 ]
02 Classic CNV > 0% to < 50%
TAP 1999 89/202 46/103 0.99 [ 0.76, 1.29 ]
03 Classic CNV > 50% (predominantly classic)
TAP 1999 52/159 51/84 0.54 [ 0.41, 0.71 ]
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
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Analysis 01.06. Comparison 01 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 06 Classic CNV subgroups: >=3 lines lost at 24 months
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 06 Classic CNV subgroups: >=3 lines lost at 24 months
Study PDT Placebo Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
01 No classic CNV
TAP 1999 18/41 14/20 7.0 0.63 [ 0.40, 0.98 ]
VIP 2001 91/166 63/92 30.0 0.80 [ 0.66, 0.97 ]
Subtotal (95% CI) 207 112 37.0 0.77 [ 0.64, 0.92 ]
Total events: 109 (PDT), 77 (Placebo)
Test for heterogeneity chi-square=0.95 df=1 p=0.33 I² =0.0%
Test for overall effect z=2.89 p=0.004
02 Classic CNV > 0 to < 50%
TAP 1999 106/202 58/104 28.4 0.94 [ 0.76, 1.17 ]
VIP 2001 19/38 10/18 5.0 0.90 [ 0.53, 1.52 ]
Subtotal (95% CI) 240 122 33.4 0.93 [ 0.77, 1.14 ]
Total events: 125 (PDT), 68 (Placebo)
Test for heterogeneity chi-square=0.02 df=1 p=0.88 I² =0.0%
Test for overall effect z=0.66 p=0.5
03 Classic CNV > 50% (predominantly classic)
TAP 1999 65/159 57/83 27.7 0.60 [ 0.47, 0.75 ]
VIP 2001 10/16 3/3 1.9 0.63 [ 0.43, 0.91 ]
Subtotal (95% CI) 175 86 29.6 0.60 [ 0.48, 0.75 ]
Total events: 75 (PDT), 60 (Placebo)
Test for heterogeneity chi-square=0.06 df=1 p=0.81 I² =0.0%
Test for overall effect z=4.54 p<0.00001
Total (95% CI) 622 320 100.0 0.77 [ 0.69, 0.87 ]
Total events: 309 (PDT), 205 (Placebo)
Test for heterogeneity chi-square=10.36 df=5 p=0.07 I² =51.7%
Test for overall effect z=4.41 p=0.00001
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
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Analysis 01.07. Comparison 01 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 07 Overall effect: contrast sensitivity: >= 6 letters lost at 24 months
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 07 Overall effect: contrast sensitivity: >= 6 letters lost at 24 months
Study PDT Placebo Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
TAP 1999 86/402 94/207 0.47 [ 0.37, 0.60 ]
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
Analysis 01.08. Comparison 01 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 08 Overall effect: contrast sensitivity: >= 15 letters lost at 24 months
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 08 Overall effect: contrast sensitivity: >= 15 letters lost at 24 months
Study PDT Placebo Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
TAP 1999 27/402 24/207 0.58 [ 0.34, 0.98 ]
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
Analysis 01.09. Comparison 01 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 09 Adverse effects: acute severe visual acuity decrease
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 09 Adverse effects: acute severe visual acuity decrease
Study PDT Placebo Risk Difference (Fixed) Weight Risk Difference (Fixed)
n/N n/N 95% CI (%) 95% CI
TAP 1999 3/402 0/207 64.4 0.01 [ 0.00, 0.02 ]
VIP 2001 10/225 0/114 35.6 0.04 [ 0.01, 0.07 ]
Total (95% CI) 627 321 100.0 0.02 [ 0.01, 0.03 ]
Total events: 13 (PDT), 0 (Placebo)
Test for heterogeneity chi-square=7.71 df=1 p=0.006 I² =87.0%
Test for overall effect z=3.12 p=0.002
-1.0 -0.5 0 0.5 1.0
Favours PDT Favours placebo
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Analysis 01.10. Comparison 01 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 10 Adverse effects: visual disturbance
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 10 Adverse effects: visual disturbance
Study PDT Placebo Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
TAP 1999 89/402 32/207 55.0 1.43 [ 0.99, 2.07 ]
VIP 2001 94/225 26/114 45.0 1.83 [ 1.26, 2.66 ]
Total (95% CI) 627 321 100.0 1.61 [ 1.24, 2.09 ]
Total events: 183 (PDT), 58 (Placebo)
Test for heterogeneity chi-square=0.85 df=1 p=0.36 I² =0.0%
Test for overall effect z=3.59 p=0.0003
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
Analysis 01.11. Comparison 01 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 11 Adverse effects: injection site
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 11 Adverse effects: injection site
Study PDT Placebo Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
TAP 1999 64/402 12/207 64.5 3.08 [ 1.62, 5.84 ]
VIP 2001 18/225 6/114 35.5 1.57 [ 0.60, 4.06 ]
Total (95% CI) 627 321 100.0 2.54 [ 1.50, 4.31 ]
Total events: 82 (PDT), 18 (Placebo)
Test for heterogeneity chi-square=1.34 df=1 p=0.25 I² =25.1%
Test for overall effect z=3.46 p=0.0005
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
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Analysis 01.12. Comparison 01 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 12 Adverse effects: infusion-related back pain
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 12 Adverse effects: infusion-related back pain
Study PDT Placebo Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
TAP 1999 10/402 0/207 49.8 11.10 [ 0.65, 190.40 ]
VIP 2001 5/225 0/114 50.2 5.71 [ 0.31, 104.21 ]
Total (95% CI) 627 321 100.0 8.40 [ 1.11, 63.58 ]
Total events: 15 (PDT), 0 (Placebo)
Test for heterogeneity chi-square=0.10 df=1 p=0.75 I² =0.0%
Test for overall effect z=2.06 p=0.04
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
Analysis 01.13. Comparison 01 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 13 Adverse effects: allergic reactions
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 13 Adverse effects: allergic reactions
Study PDT Placebo Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
TAP 1999 8/402 3/207 49.7 1.38 [ 0.36, 5.26 ]
VIP 2001 3/225 3/114 50.3 0.50 [ 0.10, 2.52 ]
Total (95% CI) 627 321 100.0 0.94 [ 0.34, 2.56 ]
Total events: 11 (PDT), 6 (Placebo)
Test for heterogeneity chi-square=0.90 df=1 p=0.34 I² =0.0%
Test for overall effect z=0.13 p=0.9
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
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Analysis 01.14. Comparison 01 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 14 Adverse effects: photosensitivity reactions
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 14 Adverse effects: photosensitivity reactions
Study PDT Placebo Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
TAP 1999 14/402 0/207 32.5 15.49 [ 0.92, 260.96 ]
VIP 2001 1/225 1/114 67.5 0.50 [ 0.03, 8.14 ]
Total (95% CI) 627 321 100.0 5.37 [ 1.01, 28.60 ]
Total events: 15 (PDT), 1 (Placebo)
Test for heterogeneity chi-square=3.32 df=1 p=0.07 I² =69.9%
Test for overall effect z=1.97 p=0.05
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
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